Guangzhou Benhealth Biopharmaceutical

Guangzhou Benhealth Biopharmaceutical is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic and inflammatory conditions. The company's lead clinical candidate, BH-011, is a highly selective URAT1 inhibitor designed to treat hyperuricemia and chronic gout by promoting uric acid excretion. Beyond its lead program, Benhealth is advancing a pipeline of early-stage assets targeting various metabolic pathways to address significant unmet medical needs. The company leverages its internal R&D capabilities and strategic location in the Guangzhou Science City biotech hub to accelerate drug development. Benhealth has received backing from regional investment groups and aims to provide safer and more effective therapeutic options for patients globally.